慢性乙型肝炎患者外周血单核细胞中载脂蛋白B mRNA编辑酶催化多肽3G的表达及其临床意义

Expression and the clinical significance of apolipoprotein B mRNA editing enzyme catalytic polypeptide 3G(APOBEC3G) in peripheral blood mononuclear cell of patients with chronic hepatitis B

目的探讨载脂蛋白B mRNA编辑酶催化多肽3G感染的不同阶段及应用不同抗病毒药物治疗期间水平的差异,推测固有免疫在抗病毒治疗中的作用。方法选择应用聚乙二醇化干扰素α-2a抗病毒治疗的慢性乙型肝炎(CHB)患者30例,口服恩替卡韦抗病毒治疗的CHB患者30例,未应用抗病毒治疗的CHB患者和乙型肝炎肝硬化代偿期患者各20例;健康成人20例为健康对照。检测CHB患者不同感染阶段及应用不同抗病毒药物期间的HBV DNA载量、ALT水平,应用荧光定量RT-PCR分析外周血单个核细胞(PBMC)中APOBEC3G mRNA的含量。结果与健康成人比较,CHB、肝硬化患者应用恩替卡韦及干扰素抗病毒治疗期间,患者PBMC中APOBEC3G mRNA的含量分别升高1.4倍(t=-3.166、P=0.003)、1.37倍(t=-2.206、P=0.0335)、1.44倍(t=-3.381、P=0.0014)和3.95倍(t=-4.790、P=0.0002)。未应用抗病毒治疗的CHB患者血中的APOBEC3G mRNA的含量与应用恩替卡韦治疗患者差异无统计学意义(t=-0.242、P=0.8097)。应用干扰素治疗的CHB患者PBMC中APOBEC3G mRNA的含量分别是未经治疗的CHB患者及应用恩替卡韦治疗患者的2.36倍(t=4.085、P=0.0002)和2.40倍(t=4.9、P<0.0001)。CHB炎患者ALT水平升高者PBMC中APOBEC3G mRNA的含量增高1.35倍,差异具有统计学意义(t=2.667、P=0.0112)。HBV DNA载量高低与A3G mRNA含量无关(F=0.2124、P=0.8871)。结论APOBEC3G在干扰素抗病毒治疗中起着重要作用。

Objective To investigate the differences between the levels of apolipoprotein B mRNA editing enzyme catalytic polypeptide 3G （APOBEC3G） in different stages of HBV infection and during the different periods treated with different antiviral drugs, and to speculate on the role of innate immunity in antiviral therapy. Methods Total of 30 cases of chronic hepatitis B （CHB） who were treated with polyethylene glycol interferon alpha-2a and 30 patients treated with entecavir were selected, 20 patients with CHB and 20 patients with hepatitis B cirrhosis were selected; while 20 healthy adults collected as controls. The HBV DNA load and ALT levels were detected, and the level of APOBEC3G mRNA in peripheral blood mononuclear cells （PBMCs） was analyzed by fluorescence quantitative PCR. Results Compared with healthy cases, during the period of using entecavir and interferon of patients with CHB and liver cirrhosis and antiviral. The levels of APOBEC3G mRNA in patients＇ PBMCs were increased by 1.4 times （t=-3.166, P=0.003）, 1.37 times （t=-2.206, P=0.0335）, 1.44 times （t=-3.381, P=0.0014） and 3.95 times （t=-4.790, P=0.0002） . There was no significant difference in the levels of APOBEC3G mRNA between the patients treated with entecavir and the patients without any treatment （t=-0.242, P=0.8097）. The levels of APOBEC3G mRNA in patients treated with interferon was 2.36 times （t=4.085, P=0.0002）, 2.40 times （t=4.9, P〈0.0001） as that in patients without any treatment and patients treated with entecavir, respectively. The levels of APOBEC3G mRNA in patients with high levels of ALT was 1.35 times higher than that of patients with normal level of ALT （t = 2.667, P = 0.0112）. The levels of HBV DNA was not related to the content of APOBEC3G mRNA （F = 0.2124, P=0.8871）. Conclusions APOBEC3G plays an important role in the antiviral therapy of interferon.